toinv,

Listening to Zenith AGM DM specifally stated that in Zenith breast cancer trial that if they saw a 40% overal response rate or higher which they expected the FDA will give them an early trial approval and registration.  AMbrx biopharma brest cancer trial they saw a 57% ORR and market gave 1000% SP increase . It will be interesting to see if Zenith releases any Breast cancer trial data soon and if the ORR is 40% or higher how the expert SP market will react.  i could see very little happening to the SP. i hope i am wrong.